4,901 trials
Healthy
Primary: Area Under the Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval, Where Tau = 12 Hours (AUCtau) of PF-04958242 — 4242; 4073 picogram*hours per…
Stroke
Primary: Feasibility and Tolerability of External Counterpulsation — 12; 9 participants
Hypertension · Isolated Systolic Hypertension (ISH)
Primary: Number of Participants With an Adverse Event (AE) — 8; 8; 7; 7 participants
Healthy Volunteer
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hour (AUC0-12h) of Oseltamivir and RO0640802 at Steady State — 581; 1143; 4147; 7966 ng*hour/mL
Lymphocytic Leukemia, Chronic
Primary: Number of Participants With Human Anti-Human Antibodies (HAHAs) — 0; 0 participants
Healthy Subjects
Primary: Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban — 179.116; 122.145 ng/mL
Prostate Cancer
Primary: Center for Epidemiological Studies-Depression Scale — 11.41; 12.43; 11.39; 9.06 units on scale — p=<.05
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose — 0.92; 0.98 h*nmol/L — p=0.02
Rectal Cancer
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0 mg/m^2
Overactive Bladder
Primary: Area Under the Concentration Time Curve From 0 to Infinity (AUC0-∞) After a Single Oral Dose of Vibegron 100 mg — 4.10; 3.23 uM•hr
Non Small Cell Lung Cancer
Primary: Cmax of Simvastatin — 24.54; 18.65 ng/mL
Neuroblastoma
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 2; 4; 0; 5 participants
Severe Hypertriglyceridemia
Primary: Baseline-adjusted AUC0-24 for Plasma Total EPA + Total DHA — 17000; 18000; 12500 hr*nmol/mL — p=0.2702
Healthy Volunteers
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) — 3; 3; 1; 1 participants
Parkinson Disease
Primary: Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1) — 182; 794; 1540; 176 ng/mL